The primary objective of the study is to study the effects of pelvic floor physiotherapy compared to treatment with α1-blocking agents in men with lower urinary tract symptoms.The secondary objective is to study the effects of the two therapies on…
ID
Source
Brief title
Condition
- Urinary tract signs and symptoms
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The primary outcome parameter is the change in lower urinary tract symptom
score as measured with the International Prostate Symptom Scale (IPSS)
Secondary outcome
Secondary outcome measures are the mean and maximum flow, as measured with free
uroflowmetry, sexual functioning measured with the MLUTSsex questionnaire,
quality of life, as measured with a quality of life question added to the IPSS
(condition specific) and with the EQ-5D (generic quality of life) and global
perception of improvement (GPI).
Background summary
The standard treatment in general practice for men with Lower Urinary Tract
Symptoms, (LUTS) is with drugs from the class of alpha1-receptor blocking
agents. Pelvic floor muscle training may be an alternative for drug treatment
of LUTS: it is harmless and has no side effects. The effects of pelvic floor
muscle training have not yet been studied in a randomized clinical trial,
comparing this treatment with the standard treatment. The hypothesis is that
pelvic floor muscle training has a favorable effect on the symptoms and
improves the quality of life of men with LUTS in general practice more than the
standard treatment with medication.
Study objective
The primary objective of the study is to study the effects of pelvic floor
physiotherapy compared to treatment with α1-blocking agents in men with lower
urinary tract symptoms.
The secondary objective is to study the effects of the two therapies on quality
of life, the maximal and mean flow of urine, sexual functioning and to study
the patient*s global impression of improvement.
A pilot is necessary to study the feasibility of the recruitment procedure, the
protocol for the pelvic floor physiotherapy and the measures of spread of the
outcome parameters in a general practice population.
Study design
The design of the study is an open label, randomized controlled trial. Patients
will be randomized 1:1 to a group receiving pelvic floor exercises or to a
group receiving medication. The follow up period is 3 months.
Intervention
The patient group randomized to pelvic floor physiotherapy will be referred to
a registered pelvic floor physiotherapist. In 6-9 sessions the patient will be
educated on the role and function of the pelvic floor muscles in LUTS and on
how to use this muscles to improve the micturition. The patient group
randomized to the standard treatment with medication will be prescribed α1-
receptor blocking agents (tamsulosin or alfuzosin) by his general practitioner.
Duration of the two interventions is three months
Study burden and risks
The risks of the study are minimal, as all investigations are non-invasive. The
treatment in the medication group is non-experimental and the treatment in the
pelvic floor exercise group has no side-effects.
The burden of the study for the participants consists of filling in
questionnaires, keeping a day bladder diary, undergoing a digital rectal
examination and a measurement of the electrical activity of the pelvic floor
muscles, urinating in a uroflowmeter and having a ultrasound examination of the
lower abdomen to assess the post-void residual volume.
The results of the study may contribute to our knowledge about alleviating
symptoms of the lower urinary tract in men. Pelvic floor physiotherapy may turn
to be an alternative for drug treatment
Antonius Deusinglaan 1 / Postbus 196
9700 AD Groningen
NL
Antonius Deusinglaan 1 / Postbus 196
9700 AD Groningen
NL
Listed location countries
Age
Inclusion criteria
Age 50 years or older
LUTS symptoms, operationalised as an IPSS score of 8 and higher
Interpretable flow (minimal production of 100 ml of urine)
No urological diseases or treatments other than LUTS
Exclusion criteria
Terminal stage of disease (according to the general practitioner)
Psychiatric or cognitive disorders (according to the general practitioner)
Contra-indication for prescribing α1-blocking agents
Abnormal prostate gland as found by digital rectal examination
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL36624.042.11 |